BioCentury
ARTICLE | Financial News

Pari spinout Breath raises €43.5M series A

March 8, 2017 6:55 PM UTC

Respiratory disease company Breath Therapeutics Holding B.V. (Munich, Germany) debuted with a €43.5 million ($46.2 million) series A round co-led by Gimv and Sofinnova Partners, with Gilde Healthcare also participating. Spun out of Pari GmbH (Starnberg, Germany), Breath is developing a drug/device combination to deliver an inhalable formulation of liposomal cyclosporine A to treat bronchiolitis obliterans syndrome (BOS).

BOS is an Orphan respiratory disease that affects lung transplant patients. Breath’s product uses Pari's eFlow nebulizer technology to deliver immunosuppressive medication to the lungs, and includes a remote adherence monitoring system. The company expects to begin Phase III trials of the candidate by early 2019...

BCIQ Company Profiles

Pari GmbH